Last reviewed · How we verify

Nefopam administration and prelevment — Competitive Intelligence Brief

Nefopam administration and prelevment (Nefopam administration and prelevment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-opioid analgesic; monoamine reuptake inhibitor. Area: Pain Management.

marketed Non-opioid analgesic; monoamine reuptake inhibitor Norepinephrine transporter, dopamine transporter, serotonin transporter Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Nefopam administration and prelevment (Nefopam administration and prelevment) — University Hospital, Rouen. Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nefopam administration and prelevment TARGET Nefopam administration and prelevment University Hospital, Rouen marketed Non-opioid analgesic; monoamine reuptake inhibitor Norepinephrine transporter, dopamine transporter, serotonin transporter
bupropion & Citalopram bupropion & Citalopram University of Colorado, Denver marketed Antidepressant combination (NDRI + SSRI) Norepinephrine transporter, dopamine transporter, serotonin transporter
Nefopam ampule Nefopam ampule Ministry Of Health / Nineveh Health Directorate phase 3 Non-opioid analgesic; monoamine reuptake inhibitor Norepinephrine transporter, dopamine transporter, serotonin transporter
Tesomet "High dose" in fed condition Tesomet "High dose" in fed condition Saniona marketed Monoamine reuptake inhibitor + biguanide combination Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase
Tesomet "Low dose" in fasted condition Tesomet "Low dose" in fasted condition Saniona marketed Monoamine reuptake inhibitor + biguanide combination Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase
néfopam néfopam University Hospital, Bordeaux marketed Non-opioid analgesic; monoamine reuptake inhibitor Norepinephrine transporter (NET); dopamine transporter (DAT); serotonin transporter (SERT)
Centanafadine SR Centanafadine SR Otsuka Pharmaceutical Development & Commercialization, Inc. phase 3 Triple monoamine reuptake inhibitor Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-opioid analgesic; monoamine reuptake inhibitor class)

  1. Ministry Of Health / Nineveh Health Directorate · 1 drug in this class
  2. University Hospital, Bordeaux · 1 drug in this class
  3. University Hospital, Rouen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nefopam administration and prelevment — Competitive Intelligence Brief. https://druglandscape.com/ci/nefopam-administration-and-prelevment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: